May success chase you as you move ambitiously towards achieving your goals and bring us more wonderful opportunities to work together.
Employers and insurers are responding to costs of expensive drugs like Sovaldi with step therapy, or higher tiers of drug-payment categories, and shifting the site of care from hospitals to physician offices, says John Santilli, partner in Access Market Intelligence. Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7
“[Hepatitis C] is a very competitive market, as a number of companies are looking to compete with Gilead’s products due to the large population of patients and the high earnings potential for drug sales,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7
New oral therapies Biogen Idec’s dimethyl fumarate is one of the new market entrants driving the shift to oral therapy growth in MS treatment, according to John Santilli of Access Market Intelligence, which provides business information to the pharmaceutical and healthcare industries. “Although this is Tecfidera’s first incident tied to PML use in more than 100,000 […]
“Cyramza, approved earlier this year for stomach cancer, is a key product in Lilly’s oncology portfolio,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. “With the colorectal cancer market becoming increasingly crowded, Lilly will need to review the pricing strategy for Cyramza to make sure the drug remains competitive […]